Shanghai Pharmaceuticals Holding Co Class H ((SHPMF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shanghai Pharmaceuticals Holding Co. is conducting a Phase II study titled ‘Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.’ The study aims to evaluate the safety and efficacy of the drug SPH4336 when used alongside endocrine therapy in patients with HR-positive, HER2-negative breast cancer that has metastasized to the brain. This research is significant as it targets a challenging condition with limited treatment options.
The intervention being tested includes SPH4336 tablets, which are administered orally, in combination with other endocrine therapies such as Letrozole, Fulvestrant, and Exemestane. These treatments aim to improve patient outcomes by targeting cancer growth.
The study follows an interventional design with a single-group model and no masking, focusing primarily on treatment. This straightforward design allows for a clear assessment of the drug’s effects in the targeted patient group.
The study began on May 14, 2023, with primary completion expected by August 15, 2025. These dates are crucial for tracking progress and anticipating results that could influence treatment protocols and market dynamics.
The update on this study may positively impact Shanghai Pharmaceuticals’ stock performance and investor sentiment, as successful outcomes could lead to new market opportunities. The study’s focus on a niche yet critical area of breast cancer treatment may also set the company apart from competitors.
The study is currently ongoing, with further details available on the ClinicalTrials portal.